Back to Agenda
The Needs of the Payers Shape the Evidence for Market Access
Session Chair(s)
Stanislav Primozic
Head, Sector for Pharmacoeconomics, Pharmacovigilance and HTA, Agency for Medicinal Products and Medical Devices, Slovenia
Session in development
Learning Objective : Understand the EU Adaptive Pathway and its potential impact on member state’s decisions on pricing and reimbursement
Speaker(s)
Marlene Gyldmark
, F. Hoffmann- La Roche AG, Switzerland
How Companies Fit All Evidence Requirements into One Development Plan
Steffen Thirstrup, MD
Chief Medical Officer, European Medicines Agency, Netherlands
How Will Payers React to the Future of Drug Development?
Jane Moseley, DrMed, MSc
Head of Inspections, European Medicines Agency, Netherlands
How Can a Joint Regulatory-HTA Scientific Advice Process (Both Pre- and Post-Launch) Help Deliver the Right Evidence?
Have an account?